Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in  and 
 by unknown
Rudd et al. BMC Cancer 2014, 14:884
http://www.biomedcentral.com/1471-2407/14/884RESEARCH ARTICLE Open AccessMutational analysis of the tyrosine kinome in
serous and clear cell endometrial cancer uncovers
rare somatic mutations in TNK2 and DDR1
Meghan L Rudd1, Hassan Mohamed1, Jessica C Price1, Andrea J O’Hara1, Matthieu Le Gallo1, Mary Ellen Urick1, NISC
Comparative Sequencing Program2, Pedro Cruz3, Suiyuan Zhang3, Nancy F Hansen3, Andrew K Godwin4,
Dennis C Sgroi5, Tyra G Wolfsberg3, James C Mullikin2,3, Maria J Merino6 and Daphne W Bell1*Abstract
Background: Endometrial cancer (EC) is the 8th leading cause of cancer death amongst American women. Most
ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are
clinically aggressive tumors for which alternative therapeutic approaches are needed. The purpose of this study was
to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can
point to potential therapeutic targets.
Methods: In a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the
catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs. For somatically
mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and
sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid). We assessed the copy
number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used
immunoblotting to measure expression of these kinases in endometrial cancer cell lines.
Results: Overall, we identified somatic mutations in TNK2 (tyrosine kinase non-receptor, 2) and DDR1 (discoidin
domain receptor tyrosine kinase 1) in 5.3% (6 of 112) and 2.7% (3 of 112) of ECs. Copy number gains of TNK2 and
DDR1 were identified in another 4.5% and 0.9% of 112 cases respectively. Immunoblotting confirmed TNK2 and
DDR1 expression in endometrial cancer cell lines. Three of five missense mutations in TNK2 and one of two
missense mutations in DDR1 are predicted to impact protein function by two or more in silico algorithms. The
TNK2P761Rfs*72 frameshift mutation was recurrent in EC, and the DDR1R570Q missense mutation was recurrent across
tumor types.
Conclusions: This is the first study to systematically search for mutations in the tyrosine kinome in clear cell
endometrial tumors. Our findings indicate that high-frequency somatic mutations in the catalytic domains of the
tyrosine kinome are rare in clear cell ECs. We uncovered ten new mutations in TNK2 and DDR1 within serous and
endometrioid ECs, thus providing novel insights into the mutation spectrum of each gene in EC.
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Endometrial carcinomas (ECs) arise from the inner
epithelial lining of the uterus and can be classified into
a number of discrete histological subtypes (reviewed in
[1]). Endometrioid endometrial carcinomas (EECs) repre-
sent the vast majority of diagnosed cases [1]. They are
generally estrogen-dependent tumors that are associated
with a number of well-established epidemiological risk
factors that lead to unopposed estrogen exposure includ-
ing obesity, nulliparity, early age at menarche, and late age
at menopause [2]. Most EECs are detected at an early
clinical stage when surgery or surgery with adjuvant
radiotherapy can often be curative [3,4].
Serous and clear cell ECs are high-grade tumors that
are rare at diagnosis but are clinically aggressive and
contribute substantially to mortality from endometrial
cancer (reviewed in [5]). For example, in a large retro-
spective study of 5,694 cases of endometrial cancer in
the US, serous and clear cell tumors together represented
13% of diagnoses but accounted for 47% of deaths [6].
Historically, serous and clear cell ECs are considered to be
estrogen-independent tumors with no well-established
epidemiological risk factors other than increasing age
[7,8]. However, a recent large epidemiological study has
suggested that increased body mass index may be a risk
factor for serous endometrial carcinomas [9]. Current
therapeutic approaches to treat patients with serous or
clear cell ECs are variable but generally include surgery
and adjuvant chemotherapy and/or radiotherapy [10,11].
Alternative therapeutic options are being sought for
patients with serous or clear cell EC and for patients with
advanced-stage or recurrent endometrioid EC. Rationally-
designed therapeutics targeting tyrosine kinases can be
clinically efficacious against tumors that have somatically
mutated, amplified, or rearranged the target kinase, and
which are dependent on the aberrant kinase-mediated
signaling for their survival [12-17]. Recently, the tyrosine
kinase gene family has been sequenced in 133 serous ECs,
329 endometrioid ECs, 53 ECs of unspecified histology,
and 13 mixed histology ECs either by targeted sequencing
of the tyrosine kinome [18], or by comprehensive se-
quencing of all protein-encoding genes including the
tyrosine kinome [19-24]. However, it has been estimated
that at least 500 tumors of a given histology need to be
sequenced to provide adequate statistical power to reliably
detect mutations occurring at a frequency of at least
3% in a particular histotype [25]. Therefore, sequen-
cing tyrosine kinase genes in additional serous ECs
may shed further insights into the frequency and
spectrum of mutations in potentially druggable targets
in this clinically aggressive subtype. Moreover, the lack
of a systematic search for mutations in the tyrosine
kinome of clear cell ECs merits such an analysis for
this histological subtype.Here, we performed a mutation discovery screen to
determine the incidence of somatic mutations in the
catalytic domains of 86 tyrosine kinases in a series of 24
primary serous, 11 clear cell, and 5 mixed (serous-endo-
metrioid) histology ECs. Somatically mutated genes were
then resequenced from another 72 ECs, and evaluated for
copy number alterations in all 112 tumors. We report
low-frequency somatic mutations and copy number gains
of the TNK2 (tyrosine kinase non-receptor, 2) and DDR1
(discoidin domain receptor tyrosine kinase 1) kinases
among the three major histological subtypes of EC.
Methods
Ethics statement
The NIH Office of Human Subjects Research determined
that this research activity was exempt from Institutional
Review Board review.
Clinical specimens
Anonymized, fresh-frozen, primary tumor tissues and
matched histologically normal tissues were obtained from
the Cooperative Human Tissue Network (100 cases),
which is funded by the National Cancer Institute, or
from the Biosample Repository at Fox Chase Cancer
Center, Philadelphia PA (1 case). DNAs from another
11 cases of fresh-frozen tissue, including all five mixed
histology (endometrioid-serous) cases (Additional file 1),
were purchased from Oncomatrix. To the best of our
knowledge, the mixed-histology tumor tissues were not
macrodissected to separate individual histological compo-
nents prior to DNA extraction by Oncomatrix. The entire
cohort of 112 cases consisted of 45 serous, 21 clear cell,
41 endometrioid, and 5 mixed histology ECs. The
endometrioid cases consisted of grade 1 (n = 26), grade
2 (n = 12), grade 2/3 (n = 1), and grade 3 (n = 2) tumors
(Additional file 1). All primary tumor tissues were col-
lected prior to treatment. For tumor tissues (n = 100) pro-
cured from CHTN, a hematoxylin and eosin (H&E)
stained section was cut from each tumor specimen and
reviewed by a pathologist to verify histology and to delin-
eate regions of tissue with a tumor cell content of ≥70%.
Nucleic acid isolation
Genomic DNA was isolated from macrodissected tissue
with greater than 70% tumor cellularity using the Pure-
gene kit (Qiagen).
Identity testing
Paired tumor-normal DNA samples were genotyped
using the Coriell Identity Mapping kit (Coriell). Genotyp-
ing fragments were size separated on an ABI-3730xl DNA
analyzer (Applied Biosystems). Alleles were scored using
GeneMapper software.
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and variant calling
M13-tailed primer pairs (Additional file 2) were designed
to target 577 of 591 exons that encode the catalytic
domains of the 86 protein tyrosine kinases (Additional
file 3), using previously published methods [26]. Sequence
constraints precluded the design of primers for 14 of 591
exons. Primers were also designed to target the exons that
encode the exonuclease domain (exons 3 to 13) of POLE
(polymerase (DNA directed), epsilon, catalytic subunit)
and are available on request. PCR amplification conditions
are available upon request. Bidirectional Sanger sequen-
cing of PCR products and subsequent nucleotide variant
calling were performed as previously described [27].
Variant positions were cross-referenced to the dbSNP
(Build 129) database to annotate and exclude known
germline variants. To determine whether novel vari-
ants were somatic mutations or germline variants, the
appropriate tumor DNA and matched normal DNA
were re-amplified in an independent PCR followed by
sequence analysis of the variant position. Primers used
in the secondary screen of TNK2 and DDR1 are provided
in Additional file 4.
Quantitative real-time PCR
Predesigned primers targeting TNK2 (VPH103-1002824A),
DDR1 (VPH106-0859748A) and B2M (beta-2-microglobu-
lin) (VPH115-0515670A) were purchased from SABios-
ciences (Qiagen). Reactions were assembled to contain
either Taqman control genomic DNA (Applied Biosys-
tems) or 2 ng of tumor genomic DNA, 2 μl of primers
(diluted 1:4), 3.5 μl SYBR Green Rox qPCR mastermix
(Qiagen), to a final 10 μl reaction volume. qPCR was
preformed on a ABI 7900 HT Fast Real-Time PCR
System (Applied Biosystems) with the following cycle
conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles
of 95°C for 15 sec and 60°C for 1 min. A standard curve
was generated with Taqman control genomic DNA, to
permit a determination of the absolute quantitation using
SDS 2.4 software (Applied Biosystems). For each experi-
ment, tumor samples were assayed in triplicate for the
target gene and control gene (B2M). For each sample, the
mean quantity of each target gene was normalized to the
mean quantity of B2M. For tumors displaying copy num-
ber gains (defined here as a ≥3-fold increase of the target
gene compared to B2M), the matched normal DNAs were
analyzed to confirm that the copy number gain was som-
atic. Three independent experiments were performed for
each tumor and normal pair. The fold change in somatic
copy number was determined by dividing the normalized
mean quantity of the target gene in the tumor sample by
the normalized mean quantity of the target gene in the
matched normal sample. In addition, a 2-tailed Student
t-test was used to calculate statistical significance.Estimation of statistical power of study design
The estimated power to detect one gene mutation in a
set of 40 tumors was calculated as 1 - (1-X)^40, where X
is the actual fraction of tumors with a mutation in that
gene (Additional file 5).
Cell lines and immunoblotting
Serous endometrial cancer cell lines (ARK1 and ARK2)
were kindly provided by Dr. Alessandro Santin (Yale
School of Medicine). RL-95-2, HEC1A, HEC1B, KLE were
obtained from the American Type Culture Collection,
or the National Cancer Institute’s Developmental Ther-
apeutics Program. RL95-2 was established from a grade
2 moderately differentiated adenosquamous carcinoma
of the endometrium [28], KLE was established from a
poorly differentiated endometrial carcinoma [29], HEC1A
was established from a human moderately differentiated
endometrial adenocarcinoma [30,31], and HEC1B is a sub-
line of HEC1A [31,32]. Cells were washed in phosphate-
buffered saline then lysed with ice-cold RIPA buffer
(Thermo Scientific) containing 1 mM Na-orthovanadate,
10 mM NaF, and 1X protease inhibitor cocktail (Roche).
Lysates were centrifuged and proteins were quantitated
with the Bio-Rad protein assay (Bio-Rad 500–0006). Equal
amounts (μg) of the cleared lysate were denatured at 95°C
in 2X SDS sample buffer (Sigma) prior to SDS-PAGE and
transfer to PVDF membranes (Bio-Rad). Primary and
HRP-conjugated secondary antibodies were: αDDR1 (Cell
Signaling), αTNK2 (Upstate), αβ-Actin (Sigma), goat anti-
mouse HRP (Cell Signaling), and goat anti-rabbit HRP
(Cell Signaling). Immunoreactive proteins were visualized
with enhanced chemiluminescence (Pierce).
Results
The TNK2 and DDR1 tyrosine kinases are somatically
mutated in endometrial carcinomas
In a mutation discovery screen, we sequenced 577 exons
that encode the catalytic domains of 86 tyrosine kinases
(Additional file 3), from 24 serous, 11 clear cell, and 5
mixed (serous/endometrioid) histology endometrial car-
cinomas. We selectively sequenced the catalytic domain of
each kinase because this domain can be preferentially
mutated in other cancers [12,15,33]. For a gene that has
kinase domain mutations at an actual frequency of 10%,
we estimate that a discovery screen of 24 serous tumors
has 92.0% statistical power to observe at least one muta-
tion (Additional file 5). For a discovery screen of 11 clear
cell tumors and 5 mixed histology tumors the correspond-
ing statistical power is estimated to be 68.6% and 40.9%
respectively (Additional file 5). Six serous tumors (T27,
T33, T45, T56, T65, T75) in our discovery screen were
previously subjected to whole exome sequencing [19].
We obtained high quality sequence data for 84%
(11.8 Mb) of targeted bases (14.1 Mb). After excluding
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variants that represented potential somatic mutations.
Sequencing of the matched normal DNA revealed that
two of the 24 variants were bona fide nonsynonymous
somatic mutations. The somatic mutations occurred in
TNK2 (Tyrosine kinase non-receptor protein 2) and
DDR1 (Discoidin domain receptor tyrosine kinase 1).
We therefore extended our analysis of TNK2 and DDR1
to sequence the remaining coding exons from the 40 tu-
mors in the discovery screen and to sequence all coding
exons of TNK2 and DDR1 from another 72 primary endo-
metrial tumors consisting of 10 clear cell, 21 serous, and
41 endometrioid tumors. The secondary screen revealed
nine additional nonsynonymous somatic mutations lo-
calizing to the catalytic and non-catalytic domains of the
encoded proteins (Figure 1, Additional file 6, Additional
file 7).
Overall, among the 112 tumors in this study, TNK2
was somatically mutated in 2.2% (1 of 45) of serous,
4.8% (1 of 21) of clear cell, 7.3% (3 of 41) of endome-
trioid, and 20% (1 of 5) of mixed histology endometrial
tumors. DDR1 was somatically mutated in 4.4% (2 of 45)
of serous tumors and in 2.4% (1 of 41) of endometrioid
tumors (Table 1). Of the three endometrioid tumors that
harbored somatic DDR1 or TNK2 mutations, two cases
(T88 and T117) were grade 1 and one case (T131) was
grade 3. Overall, there was no significant difference in
the frequency of TNK2/DDR1 mutations between low/
intermediate-grade and high-grade endometrioid ECs; 2




















Figure 1 Localization of nonsynonymous, somatic mutations in
TNK2 and DDR1 relative to important functional domains of
the proteins. All the somatic mutations were uncovered in primary
endometrial tumors. Individual missense mutations (black boxes) are
distinguished from frameshift mutants (black diamonds).
Abbreviations: CB, clathrin binding site; CRIB, Cdc42/Rac interactive
binding; DS, discoidin; SAM, sterile alpha motif; SH3, Src Homology
3; TM, transmembrane; UBA, ubiquitin associated.endometrioid ECs had a TNK2 or DDR1 mutation com-
pared with 1 of 3 (33.3%) high-grade (grade 2/3 or 3)
endometrioid ECs (P = 0.2086). The TNK2D572N,
TNK2R849W, TNK2R256H, and DDR1R570Q missense
mutants are predicted, by at least two in silico algo-
rithms, to impact the function of the encoded proteins
(Table 1). Immunoblotting confirmed that TNK2 and
DDR1 are endogenously expressed in endometrial cancer
cells (Figure 2).
Increased copy number of TNK2 and DDR1 in endometrial
carcinoma
We next used quantitative real-time PCR to determine
whether TNK2 or DDR1 were affected by copy number
alterations among the 112 endometrial tumors in this
study. Somatic copy number increases of TNK2 were
detected in 8.9% (4 of 45) of serous tumors and in 2.4%
(1 of 41) of endometrioid tumors, but in none of the
clear cell tumors (Table 2). The single endometrioid
tumor displaying a copy number gain of TNK2 was a
grade 2 tumor. Somatic copy number increases involving
DDR1 were detected in 2.2% (1 of 45) of serous tumors
(Table 2). For each gene, tumors that displayed copy
number alterations were distinct from tumors that had
somatic mutations (Additional file 8). Considering muta-
tions and copy number alterations together, TNK2 was
somatically altered in 11.1% (5 of 45) of serous, 4.8% (1 of
21) of clear cell, 9.8% (4 of 41) of endometrioid, and 20%
(1 of 5) of mixed histology tumors and DDR1 was somat-
ically altered in 6.7% (3 of 45) of serous and 2.4% (1 of 41)
of endometrioid tumors but not in clear cell or mixed
histology tumors (Additional file 8).
Copy number gains of TNK2 and DDR1 could reflect
either targeted gene amplification of these kinases or
gain of a multigenic genomic region encompassing these
genes. To discriminate between these two possibilities,
we interrogated the copy number status of TNK2, DDR1,
and their flanking genes within The Cancer Genome Atlas
(TCGA) catalogue of somatic alterations in serous and
endometrioid ECs [21], via the cBIO Cancer Genomics
Portal [34]. In the serous and endometrioid ECs within
the TCGA cohort, copy number gains involving TNK2
and DDR1 were not focal but extended to flanking genes.
A subset of TNK2 and DDR1 mutated tumors are
POLE-mutant or microsatellite unstable
Somatic mutations in the exonuclease domain of POLE
and/or microsatellite instability (MSI) occur in a subset
of ECs and are associated with elevated mutation rates
[21]. We therefore sought to determine whether any of
the TNK2- or DDR1-mutated cases were coincident with
POLE mutations or MSI-positivity. We sequenced exons
3–13 of POLE, which encode the exonuclease domain,
from all 112 tumors in our study; the MSI status of
Table 1 Somatic mutations of TNK2, and DDR1 identified among 112 primary ECs






In silico functional predictions
Mutation assessor SIFT Polyphen v2
TNK2 T3a,b Serous c.C1887_1888ins C p.P633Afs*3 - - -
T3a,b Serous c.G1714A p.D572N Low Affects function Probably damaging
T15a Mixed c.G415A p.V139M Low Affects function Possibly damaging
T77c Clear cell c.C2545T p.R849W Low Affects function Probably damaging
T88c Endometrioid (G1) c.G767A p.R256H High Affects function Probably damaging
T88c Endometrioid (G1) c.G126T p.K42N Medium Tolerated Probably damaging
T117c Endometrioid (G1) c.2276 del C p.P761Rfs*72 - - -
T131 Endometrioid (G3) c.2276 del C p.P761Rfs*72 - - -
DDR1 T3a,b Serous c.C1720A p.R574S Low Tolerated Benign
T79 Serous c.G1709A p.R570Q Low Affects function Probably damaging
T117c Endometrioid (G1) c.2216delA p.N740Ifs*10 - - -
Transcript accession numbers: TNK2 (Ensembl ID ENST00000392400), DDR1 (Ensembl ID ENST00000454612). Protein accession numbers: TNK2 (CCDS33928), DDR1
(CCDS4690). G: Grade.
aCase no. T3 is also known as OM-1323, T15 is also known as OM-1529.
bPOLE-mutated.
cMSI-positive tumors, as reported previously [19].
*Denotes the position of a new stop codon introduced by the corresponding frameshift (fs) mutation.
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Three tumors had somatically mutated POLE (T3
(c.C890T;p.S297F), T24 (c.1096delT; p.F367Lfs*15), and
T97 (c.C857G; p.P286R), Additional file 9). Overall, som-
atic mutations within the exonuclease domain of POLE

























Figure 2 TNK2 and DDR1 are expressed in endometrial cancer
cell lines. Immunoblots showing expression of the TNK2 and DDR1
proteins in a panel of endometrial cancer cell lines. Actin served as a
loading control.clear cell, and 2.4% (1 of 41) of endometrioid tumors in
our cohort. The frequency of POLE mutations in
TNK2-DDR1 mutated cases (1 of 7; 14%) compared
with TNK2-DDR1 non-mutated cases (2 of 105; 2%)
was not statistically significantly different (P = 0.1775).
Of the seven tumors with TNK2 or DDR1 mutations,
one case (T3) had a somatic mutation within POLE
(POLES297F) and another three cases (T77, T88, and
T117) were MSI-positive (Table 1). One of the two frame-
shift mutations in T117, an MSI-positive tumor, occurred
at a polynucleotide (Cn) tract (Additional file 6), suggest-
ing that this mutation (TNK2P761Rfs*72) may have arisen as
a consequence of defective mismatch repair.
Discussion
Herein we report the occurrence of low-frequency somatic
mutations in the TNK2 and DDR1 kinases among serous,
clear cell, and endometrioid ECs. The TNK2 non-receptor
tyrosine kinase is activated in response to a variety of
stimuli including ligand-dependent stimulation of re-
ceptor tyrosine kinases [35], Cdc42 [36], and integrin-
mediated cell adhesion [37]. TNK2 activation has been
implicated in the regulation of cell growth, survival, and
integrin-mediated cell adhesion and migration [37-41],
and overexpression of TNK2 in cultured cells promotes
a metastatic phenotype [37]. The DDR1 receptor tyro-
sine kinase is activated by triple-helical collagens [42]
and has been implicated in the regulation of cell adhe-
sion, survival, proliferation, differentiation, migration,
invasion, morphogenesis and development [43-53].
Of the seven endometrial tumors that had somatic
mutations in TNK2 and/or DDR1 in our study, one tumor
Table 2 Copy number gains of TNK2 and DDR1 among 112 primary ECs
Gene Tumor ID Histology Fold Increase in somatic copy number p-value§
TNK2 T25 Serous 3.911 0.0000426
T50 Serous 3.416 0.0018339
T66 Serous 5.065 0.0185581
T83 Serous 5.968 0.0171938
T105 Endometrioid (G2) 3.374 0.0006604
DDR1 T23 Serous 3.019 0.0005727
§2-tailed Student t-test.
G: Grade.
Rudd et al. BMC Cancer 2014, 14:884 Page 6 of 9
http://www.biomedcentral.com/1471-2407/14/884(T3) was POLE-mutant and three tumors (T77, T88, and
T117) were microsatellite-unstable, raising the possibility
that the TNK2 and DDR1 mutations in these cases may
have arisen as a consequence of replicative and mismatch
repair defects respectively. A determination of whether
the TNK2 and DDR1 mutations uncovered in this study
are pathogenic driver mutations or incidental passenger
mutations will ultimately rely on functional studies. In
the interim, the potential effects of the TNK2 and DDR1
mutations on protein function can be postulated based
on their positions relative to known functional domains
of the encoded proteins and on in silico predictions. In
this regard, the TNK2R256H mutant occurs within the
catalytic loop of TNK2, at a conserved residue that
forms a hydrogen bond with an ATP analog [54], and is
predicted, in silico, to impact protein function. The
TNK2D572N mutant occurs within a motif (LIDF) that is
essential for binding to the clathrin heavy chain [55],
and is predicted to be deleterious. Because a synthetic
mutation (TNK2D572A) at this precise residue results in
loss of clathrin binding [55], we speculate that the somatic
TNK2D572N mutant might likewise alter the TNK2-clathrin
interaction. The TNK2P761Rfs*72 mutant was recurrent in
our study occurring in two endometrioid ECs one of which
was MSI-positive. The TNK2P633Afs*3 frameshift mutation
may also be recurrent: we observed TNK2P633Afs*3
(chr3:195,595,228-195,595,229 insC; Hg19) in a POLE-
mutant serous EC and this variant has been catalogued
by others in cancer cell lines and tumors although in
those instances it has not been subjected to technical
validation (URL: http://www.cbioportal.org/public-portal/).
Both TNK2P633Afs*3 and TNK2P761Rfs*72 are predicted to en-
code truncated forms of TNK2 that lack the UBA (ubi-
quitin associated) domain, which has been implicated in
ligand-dependent proteasomal degradation of TNK2 [38,56].
An earlier observation that deletion of the UBA domain of
TNK2 results in elevated protein levels [56], together with
a report that synthetic C-terminal deletion mutants of
TNK2 retain catalytic activity [57,58], raises the possi-
bility that the naturally occurring TNK2P633Afs*3 and
TNK2P761Rfs*72 mutants found in this study might encode
elevated levels of truncated but catalytically active proteins.The three DDR1 mutations we identified in EC con-
sisted of two missense mutations (DDR1R570Q and
DDR1R574S), and a frameshift mutation (DDR1N740Ifs*10)
that occurred in an MSI-positive tumor. The DDR1R570Q
missense mutation, which we identified in a case of
serous EC that was microsatellite-stable and POLE-
wildtype, has been identified by others in an endome-
trioid EC [21], and in a case of metastatic melanoma [59].
Thus, the recurrent nature of the DDR1R570Q mutation
across studies suggests it may be a pathogenic event that
provides a selective advantage in tumorigenesis, including
endometrial tumorigenesis.
In the recent catalogue of genomic alterations reported
by TCGA for endometrioid and serous ECs, somatic
mutations of TNK2 were documented in 2% of serous
ECs and in 1% of endometrioid ECs, and somatic mu-
tations of DDR1 were noted in 4% of serous ECs and
2% of endometrioid ECs [21,34,60]. The eight muta-
tions we uncovered in TNK2 are different to the three
TNK2 mutations previously described in EC by TCGA.
Similarly, two of the three mutations we describe in
DDR1 are unique to this study whereas, as discussed
earlier, the third mutation (DDR1R570Q, CCDS4690;
alternatively annotated as DDR1R607Q, CCDS34385)
was present in a case of serous EC in this study and in
a case of endometrioid EC by TCGA. Therefore, our
observations not only validate the recent findings of
low frequency somatic mutations in TNK2 and DDR1
in serous and endometrioid ECs by TCGA [21], but
extend upon those findings by refining knowledge of
the mutation spectrum of TNK2 and DDR1 in EC.
Moreover, to our knowledge this is the first systematic
search for somatic mutations in the tyrosine kinome of
clear cell ECs.
In addition to somatic mutations, we also uncovered
copy number gains involving TNK2 at an appreciable
frequency in serous and endometrioid ECs (8.9% and
2.4% respectively), and copy number gains involving
DDR1 at low frequency (2.2%) in serous ECs in our study.
However, from an analysis of the TCGA endometrial can-
cer data, increased TNK2 and DDR1 copy number appears
to reflect regional gains rather than focal amplification,
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metrial cancer difficult to predict.
It is worth noting that our study has several limita-
tions. First, our mutation discovery screen was restricted
to the exons encoding the catalytic domains of tyrosine
kinases and would not have detected mutations present
in other exons. Second, our discovery screen did not have
high statistical power to detect moderately to infrequently
mutated genes (Additional file 5). Third, the use of Sanger
sequencing for mutational analysis, in both the discovery
screen and subsequent secondary screens of TNK2 and
DDR1, may have precluded the identification of sub-
clonal variants that are below the sensitivity of detection
by this methodology.Conclusions
In conclusion, we have identified rare somatic mutations
and copy number alterations involving the TNK2 and
DDR1 kinases amongst serous, clear cell, and endome-
trioid ECs. Our findings validate and extend the obser-
vation of TNK2 and DDR1 mutations in serous and
endometrioid ECs catalogued by TCGA. To our know-
ledge, this is the first systematic search for somatic
mutations in the tyrosine kinome of clear cell ECs. The
recurrent nature of the TNK2P761Rfs*72 and DDR1R570Q
mutants raises the possibility that these may be pathogenic
events that bestow a selective advantage in endometrial
tumorigenesis. Future mechanistic studies of the somatic
mutations reported herein are warranted.Availability of supporting data
All data supporting the somatic mutations reported in
the manuscript are provided in Additional files 6, 7 and
9. Sanger sequencing files for the entire study will be
made available through dbGAP with controlled access.Additional files
Additional file 1: Clinicopathological information for the mixed
histology and endometrioid ECs in the study cohort.
Additional file 2: PCR primers used in the discovery screen.
Additional file 3: Tyrosine kinase genes analyzed in the mutation
discovery screen.
Additional file 4: PCR primers used in the secondary screens of
TNK2 and DDR1.
Additional file 5: Estimated statistical power to detect mutations in
the discovery screen.
Additional file 6: Sequence traces showing somatic mutations
identified in TNK2. Traces encompassing the mutated nucleotide
(arrow) in tumor (T) DNA, and corresponding traces from matched
normal (N) DNA are displayed.
Additional file 7: Sequence traces showing somatic mutations
identified in DDR1. Traces encompassing the mutated nucleotide
(arrow) in tumor (T) DNA, and corresponding traces from matched
normal (N) DNA are displayed.Additional file 8: Oncoprints showing the distribution of somatic
mutations and copy number alterations of TNK2 and DDR1 among
112 primary endometrial carcinomas in the discovery screen.
Individual tumors are displayed as gray bars; somatic mutations are
indicated by dark blue bars; somatic copy number gains are indicated by
green bars. The overall frequency (%) of somatic alterations for each
histological subtype of endometrial cancer is shown on the right.
Additional file 9: Sequence traces showing somatic mutations
identified in exons 3–13 of POLE, which encode the exonuclease
domain of POLE. Traces encompassing the mutated nucleotide (arrow)
in tumor (T) DNA, and corresponding traces from matched normal (N)
DNA are displayed.
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